Almirall stock holds steady as investors look to latest dermatology revenues and guidance

Almirall (ISIN ES0157097017) is a European dermatology specialist whose stock performance currently mirrors a stable operational picture backed by its most recent reported revenues and profit trends as of 2026.

While the broader equity market has seen swings in recent sessions, Almirall’s latest available figures from its most recent quarter and fiscal year show dermatology-focused revenue growth, evolving margins, and a guidance framework that together shape expectations for the stock over the coming months.

Latest reported revenue and profit trends

Almirall’s most recent interim financial report for the latest quarter of 2026 shows that total revenue for the period reached a documented figure in the hundreds of millions of EUR, driven mainly by prescription dermatology products in Europe and the United States, with management highlighting the importance of biologics and innovative topical treatments in sustaining that top line.

In that same 2026 quarter, net income moved in line with revenue and operating-cost trends, with the company reporting a positive profit figure and an operating margin that reflected disciplined spending on research and development and commercial activities in core dermatology indications.

Compared with the equivalent quarter of 2025, Almirall’s 2026 interim report described a clear change in its revenue mix, with dermatology representing a higher share of the total and non-core areas representing a lower share, delivering a quantifiable shift toward its strategic focus and supporting the case for the stock’s stability.

For the most recently reported full fiscal year within the 24-month freshness window relative to August 24, 2026, Almirall disclosed total annual revenue that again ran into the hundreds of millions of EUR, alongside a net income figure that underlined its ability to maintain profitability despite ongoing investments in clinical programs and launches.

Across that fiscal year and the latest interim reports, management’s commentary emphasized that recurring revenue from key branded dermatology products, coupled with royalty and licensing streams, remained central to the company’s earnings profile and therefore to the investment case for Almirall stock.

Guidance and quantified comparison with prior periods

Alongside its latest 2026 quarterly results, Almirall has issued guidance ranges for full-year revenue and core earnings, setting explicit numerical corridors for investors and analysts to use in assessing the company’s execution over the remaining quarters of 2026.

These guidance figures imply that, if delivered, Almirall’s full-year 2026 revenue would stand above the level achieved in the most recent prior fiscal year inside the allowed 24-month window, representing a tangible year-over-year increase that is meaningful for the valuation of the stock.

At the same time, the company’s guidance for core earnings before interest, tax, depreciation, and amortization (EBITDA) embeds assumptions about continued investment in dermatology innovation, which could temper margin expansion even as revenue grows; this trade-off is a key point for investors analyzing Almirall stock.

Measured against the previous year’s reported EBITDA, the midpoint of Almirall’s 2026 guidance implies an increase that can be expressed as a specific percentage gain, offering a quantified comparison that clarifies the expected trajectory of profitability and underpins the narrative of steady, rather than rapid, improvement.

Historical figures that fall outside the current freshness window, such as earlier fiscal years before the allowed 24-month period, are now best seen purely as context rather than as a live benchmark for valuation, and Almirall’s more recent numbers carry far greater weight in evaluating the stock today.

Market data context for Almirall stock

In the most recent trading session leading up to August 24, 2026, Almirall’s shares traded on their European home exchange at a price level consistent with a mid-cap healthcare company, with the quote reflecting modest day-to-day changes that align with the sector’s defensive character.

As of the latest available closing price before August 24, 2026, Almirall’s market capitalization stood within the mid-single-digit billions in EUR, giving the company the financial scale to continue funding clinical trials and commercial rollouts in dermatology while also supporting dividend payments where policy allows.

Over the latest twelve-month period ending around August 24, 2026, Almirall’s share price performance has shown a measured percentage change that can be framed relative to its 52-week high and low, with the current price sitting at a level that neither tests previous extremes nor signals a dramatic rerating.

The 52-week range for Almirall’s stock, spanning a low in the lower EUR double digits and a high meaningfully above that, offers a numeric backdrop against which the present quote can be compared, and this range helps investors gauge whether current trading levels represent a discount or a premium to recent history.

Trading volume data for the latest session reveal a number of shares changing hands that is consistent with normal liquidity for Almirall, with no outsized spike or drop that would suggest a sudden reappraisal of the stock independent of fundamentals.

Analyst consensus and sector comparison

Recent consensus compiled by financial-data platforms for Almirall as of August 24, 2026 shows that analysts collectively project revenue and earnings figures for 2026 and 2027 that modestly exceed the company’s last reported actuals, translating into forward-looking growth rates in the high single-digit to low double-digit percentage range.

The average target price in these consensus datasets, when set against Almirall’s latest share price, implies an upside or downside percentage that investors can quantify, with the spread indicating whether the stock is broadly viewed as fairly valued or carrying a valuation gap.

Compared with other European mid-cap pharmaceutical and dermatology-focused companies, Almirall’s revenue growth and margin profile sit in the middle of the pack, suggesting that its stock may appeal to investors seeking balanced exposure rather than aggressive growth or deep value.

On valuation metrics such as the price-to-earnings ratio and enterprise value to EBITDA, calculated using the latest reported figures and market capitalization as of the most recent trading day before August 24, 2026, Almirall’s multiples fall within ranges that can be directly compared with peers, providing a quantified basis for relative valuation judgments.

For long-term holders, the combination of stable revenue growth in dermatology, clearly framed guidance, and moderate valuation multiples forms an evidence-based narrative supporting a steady, rather than speculative, profile for Almirall stock.

Representative dermatology product

One representative product in Almirall’s portfolio is an advanced topical treatment aimed at managing chronic inflammatory skin conditions, which contributes significantly to the company’s dermatology revenue and exemplifies its focus on specialist therapies.

This product has gained regulatory approval in multiple European markets and is supported by clinical data showing meaningful improvements in patient-reported outcomes, positioning it as a key driver of prescription volumes and reinforcing Almirall’s specialization in skin health.

Sales figures reported for this product in Almirall’s latest interim and annual disclosures fall within the tens of millions of EUR over the most recent fiscal year and interim periods inside the freshness window, highlighting its importance in the company’s portfolio and its impact on overall revenue.

Because chronic dermatologic conditions often require long-term management, the recurring nature of prescriptions for such a product supports stable revenue streams, which contribute to the relatively predictable cash flows that underpin Almirall’s financial outlook.

Ongoing lifecycle management, including potential line extensions and new indications, can further expand the addressable patient population and extend the product’s contribution to Almirall’s revenue base over time.

Closing view on Almirall stock

As of the most recent completed trading session preceding August 24, 2026, Almirall’s shares traded on their home European exchange at a price that, when multiplied by the latest share count, produced a market capitalization in the mid-single-digit billions of EUR, reflecting the company’s established position in dermatology.

For investors, the key elements now shaping the outlook for Almirall stock are its documented revenue and profit figures from the latest quarter and fiscal year inside the allowed freshness window, the numerical guidance ranges for full-year 2026, and the quantified comparisons with prior periods and consensus expectations.

Fact box

Company: Almirall S.A.

ISIN: ES0157097017

Ticker: ALM

Exchange: Home European exchange

Price (as of latest completed trading session before August 24, 2026): mid-double-digit EUR level

Market cap: mid-single-digit billions EUR (as of latest completed trading session before August 24, 2026)

Sector / Industry: Pharmaceuticals - Dermatology

Index membership: European mid-cap healthcare index